ALLMedicine™ Hypopituitarism Center
Research & Reviews 890 results
https://doi.org/10.1016/j.wneu.2023.03.085
World Neurosurgery; Simander G, Dahlqvist P et. al.
Mar 27th, 2023 - To investigate the association between intraoperative intrasellar pressure (ISP) and pre- and postoperative endocrine disturbances with focus on hyperprolactinemia and hypopituitarism in patients with pituitary tumours. The study is a consecutive,...
https://doi.org/10.1053/j.semnuclmed.2023.02.005
Seminars in Nuclear Medicine; Gillett D, MacFarlane J et. al.
Mar 26th, 2023 - Tumors of the pituitary gland, although mostly benign adenomas, are a cause of significant morbidity and even excess mortality due to local compressive effects (eg visual loss, hypopituitarism) and unregulated hormone secretion (eg acromegaly or C...
https://doi.org/10.1177/19714009231166075
The Neuroradiology Journal; Tartuci IT, Junior NADS et. al.
Mar 24th, 2023 - Intracranial xanthogranulomas (XGs) have been found at various sites, but xanthogranuloma of the sellar region is extremely rare. We report about a case of sellar XG in a 34-year-old female. Magnetic resonance imaging showed a solid-cystic mass lo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969757
Best Practice & Research. Clinical Endocrinology & Metabo... Capatina C, Poiana C et. al.
Mar 7th, 2023 - There is increased interest related to the impact of coronavirus disease 19 (COVID-19) on the endocrine system and in particular on the pituitary gland. Over the course of the severe infection with acute respiratory syndrome coronavirus 2 (SARS-Co...
https://doi.org/10.2174/1871530323666230228110650
Endocrine, Metabolic & Immune Disorders Drug Targets; He H, Li DM
Mar 1st, 2023 - Pituitary stalk interruption syndrome (PSIS) is featured by hypopituitarism and a classic triad of absence or slender pituitary stalk, absence or ectopic posterior lobe, and hypoplasia of the anterior lobe. Hypopituitarism, which induces hormone d...
Guidelines 5 results
https://doi.org/10.1507/endocrj.EJ19-0163
Endocrine Journal; Arima H, Iwama S et. al.
Jun 28th, 2019 - Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve,...
https://doi.org/10.1210/jc.2016-2118
The Journal of Clinical Endocrinology and Metabolism; Fleseriu M, Hashim IA et. al.
Nov 5th, 2016 - To formulate clinical practice guidelines for hormonal replacement in hypopituitarism in adults. The participants include an Endocrine Society-appointed Task Force of six experts, a methodologist, and a medical writer. The American Association for...
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.
Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...
https://doi.org/10.1227/NEU.0000000000001389
Neurosurgery Lucas JW, Bodach ME et. al.
Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present clinically with vision loss and hypopituitarism. To characterize the existing literature as it pertains to the initial management of NFPAs. A sys...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393422
The Journal of Clinical Endocrinology and Metabolism; Freda PU, Beckers AM et. al.
Apr 9th, 2011 - The aim was to formulate practice guidelines for endocrine evaluation and treatment of pituitary incidentalomas. Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails and one in-per...
Drugs 2 results see all →
Clinicaltrials.gov 34 results
https://clinicaltrials.gov/ct2/show/NCT05675111
Jan 9th, 2023 - Immune checkpoint inhibitor (ICI) includes agents that block cytotoxic T-cell-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1). Since the FDA-approval of the CTLA-4 inhibitor...
https://clinicaltrials.gov/ct2/show/NCT05660356
Dec 21st, 2022 - Annually, over 250,000 Canadians and over 40 million individuals worldwide will suffer an uncomplicated concussion (head injury with no intracranial abnormalities seen on imaging). Most individuals will recover within weeks of injury but over 30% ...
https://clinicaltrials.gov/ct2/show/NCT05403255
Jun 3rd, 2022 - Objectives: Describe the quality of life and psychosocial repercussions of the disease in children 10-17 years of age with multiple pituitary hormone deficiency (either acquired or congenital), or isolated pituitary hormone deficiency (other than ...
https://clinicaltrials.gov/ct2/show/NCT02720952
May 4th, 2022 - This is a Phase 3, open label, single centre study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency. The study will be conducted in a total of 24 subjects, before their 6th birthday, requiring repl...
https://clinicaltrials.gov/ct2/show/NCT04648137
Apr 13th, 2022 - Disruption of the hypothalamic-pituitary axis due to congenital abnormalities, tumors or head trauma may cause anterior and/or posterior pituitary deficiency also known as partial or panhypopituitarism. Patients with hypopituitarism, especially th...
News 57 results
https://www.medscape.com/viewarticle/979314
Aug 17th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A case study of a 65-year-old man in Japan with long COVID describes how he recovered from certain impaired hormone deficiencies that persisted fo...
https://www.onclive.com/view/breast-cancer-treatment-advances-lead-to-broadened-scope-of-personalized-medicine
Mar 21st, 2022 - As a result of many positive trials throughout breast cancer in recent years, the treatment armamentarium has blossomed with CDK4/6 inhibitors, checkpoint inhibitors, and antibody-drug conjugates (ADCs) to name a few, explained Harold J. Burstein,...
https://www.medpagetoday.com/endocrinology/thyroid/97418
Feb 28th, 2022 - Switching between generic levothyroxine products won't make much of a clinical difference, a new study suggested. In a comparative effectiveness research study of 15,829 patients, those who switched up their generic levothyroxine product didn't se...
https://www.onclive.com/view/multidisciplinary-care-for-malignant-melanoma
Apr 2nd, 2021 - For High-Definition, Click The treatment of patients with metastatic melanoma requires a team approach. The complexities of this disease warrants impute from several specialists to properly deliver care, the panelists agree. Along these lines, h...
https://www.onclive.com/view/i-o-second-line-treatment
Apr 2nd, 2021 - Peter Galle, MD: What do we have as evidence? The only I/O agent that has been convincing in demonstrating benefit was atezolizumab in combination with bevacizumab in first line. That’s what we have. The monotherapy has not made it into a signific...